Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Publication year range
1.
Acta Trop ; 226: 106272, 2022 Feb.
Article in English | MEDLINE | ID: mdl-34896324

ABSTRACT

Cutaneous leishmaniasis is the most common form of leishmaniasis in humans, factors such as poverty, poor housing, inadequate domestic hygiene, malnutrition, mobility, and occupational exposure are risk factors associated with the condition, however, there are few studies focused on determining the immune mechanism involved in the resolution of cutaneous leishmaniasis caused by the species Leishmania mexicana, as well as possible environmental factors such as solar radiation, which could contribute to its establishment. through mechanisms immunosuppressants, of which to date is unknown. In this study, the effect of UV-B light was evaluated as a risk factor affecting components of the innate immune response 3 days after infection with L. mexicana. A delayed-type hypersensitivity reaction (DTH) was used to evaluate immunosuppression induced by UV-B light. Through a histological analysis, the skin lesions of the mice (Hematoxylin & Eosin) were evaluated, the presence of mast cells and their level of degranulation (toluidine blue staining), the presence of IL-10+ and MOMA2+ cells were analyzed by immunohistochemistry and finally, the cytokine profile was evaluated by qPCR in the skin lesions tissue. An alteration in the architecture of the tissue was observed, as well as a greater number of mast cells, both complete and degranulated, as well as an increase in IL-10+ and MOMA2+ cells in the skin lesions of the mice that were irradiated and subsequently infected, when compared with the lesions of infected mice (P> 0.0001), immunomodulation was also observed in the profile of cytokines expressed between both groups analyzed. This is the first study to demonstrate the effects of UV-B radiation on components of the innate immune response at short times of infection by L. mexicana.


Subject(s)
Leishmania mexicana , Leishmaniasis, Cutaneous , Animals , Immunity, Innate , Immunosuppression Therapy , Mice , Mice, Inbred BALB C
2.
Pathog Dis ; 78(8)2020 11 11.
Article in English | MEDLINE | ID: mdl-33016312

ABSTRACT

Leishmaniosis is currently considered a serious public health problem and it is listed as a neglected tropical disease by World Health Organization (WHO). Despite the efforts of the scientific community, it has not been possible to develop an effective vaccine. Current treatment consists of antimonials that is expensive and can cause adverse effects. It is essential to fully understand the immunopathogenesis of the disease to develop new strategies to prevent, treat and eradicate the disease. Studies on animal models have shown a new paradigm in the resolution or establishment of infection by Leishmania mexicana where a wide range of cytokines, antibodies and cells are involved. In recent years, the possibility of a new therapy with monoclonal antibodies has been considered, where isotype, specificity and concentration are critical for effective therapy. Would be better to create/generate a vaccine to induce host protection or produce passive immunization with engineering monoclonal antibodies to a defined antigen? This review provides an overview that includes the current known information on the immune response that are involved in the complex host-parasite relationship infection caused by L. mexicana.


Subject(s)
Adaptive Immunity , Host-Parasite Interactions , Immunity, Innate , Leishmaniasis, Cutaneous/immunology , Animals , Antibodies, Protozoan , Disease Models, Animal , Humans , Immunity , Leishmania mexicana/immunology , Mice
3.
PLoS One ; 11(6): e0157475, 2016.
Article in English | MEDLINE | ID: mdl-27303806

ABSTRACT

Pulmonary nocardiosis is a granulomatous disease with high mortality that affects both immunosuppressed and immunocompetent patients. The mechanisms leading to the establishment and progression of the infection are currently unknown. An animal model to study these mechanisms is sorely needed. We report the first in vivo model of granulomatous pulmonary nocardiosis that closely resembles human pathology. BALB/c mice infected intranasally with two different doses of GFP-expressing Nocardia brasiliensis ATCC700358 (NbGFP), develop weight loss and pulmonary granulomas. Mice infected with 109 CFUs progressed towards death within a week while mice infected with 108 CFUs died after five to six months. Histological examination of the lungs revealed that both the higher and lower doses of NbGFP induced granulomas with NbGFP clearly identifiable at the center of the lesions. Mice exposed to 108 CFUs and subsequently to 109 CFUs were not protected against disease severity but had less granulomas suggesting some degree of protection. Attempts to identify a cellular target for the infection were unsuccessful but we found that bacterial microcolonies in the suspension used to infect mice were responsible for the establishment of the disease. Small microcolonies of NbGFP, incompatible with nocardial doubling times starting from unicellular organisms, were identified in the lung as early as six hours after infection. Mice infected with highly purified unicellular preparations of NbGFP did not develop granulomas despite showing weight loss. Finally, intranasal delivery of nocardial microcolonies was enough for mice to develop granulomas with minimal weight loss. Taken together these results show that Nocardia brasiliensis microcolonies are both necessary and sufficient for the development of granulomatous pulmonary nocardiosis in mice.


Subject(s)
Disease Models, Animal , Lung/microbiology , Nocardia Infections/microbiology , Nocardia/physiology , Animals , Granuloma/pathology , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , Host-Pathogen Interactions , Humans , Lung/pathology , Mice, Inbred BALB C , Microscopy, Confocal , Nocardia/genetics , Nocardia/metabolism , Nocardia Infections/mortality , Nocardia Infections/pathology , Survival Rate , Viral Load , Weight Loss
4.
J Immunol Res ; 2015: 146305, 2015.
Article in English | MEDLINE | ID: mdl-25984538

ABSTRACT

Human dialyzable leukocyte extracts (DLEs) are heterogeneous mixtures of low-molecular-weight peptides that are released on disruption of peripheral blood leukocytes from healthy donors. DLEs improve clinical responses in infections, allergies, cancer, and immunodeficiencies. Transferon is a human DLE that has been registered as a hemoderivate by Mexican health authorities and commercialized nationally. To develop an animal model that could be used routinely as a quality control assay for Transferon, we standardized and validated a murine model of cutaneous HSV-1 infection. Using this model, we evaluated the activity of 27 Transferon batches. All batches improved the survival of HSV-1-infected mice, wherein average survival rose from 20.9% in control mice to 59.6% in Transferon-treated mice. The activity of Transferon correlated with increased serum levels of IFN-γ and reduced IL-6 and TNF-α concentrations. Our results demonstrate that (i) this mouse model of cutaneous herpes can be used to examine the activity of DLEs, such as Transferon; (ii) the assay can be used as a routine test for batch release; (iii) Transferon is produced with high homogeneity between batches; (iv) Transferon does not have direct virucidal, cytoprotective, or antireplicative effects; and (v) the protective effect of Transferon in vivo correlates with changes in serum cytokines.


Subject(s)
Cell Extracts/pharmacology , Herpes Simplex/drug therapy , Herpesvirus 1, Human/drug effects , Leukocytes/metabolism , Skin Diseases, Viral/drug therapy , Animals , Biological Assay , Cell Line , Chlorocebus aethiops , Disease Models, Animal , Herpes Simplex/virology , Interferon-gamma/blood , Interleukin-6/blood , Male , Mice , Mice, Inbred BALB C , Skin Diseases, Viral/virology , Tumor Necrosis Factor-alpha/blood , Vero Cells
5.
Bol. méd. Hosp. Infant. Méx ; 69(1): 24-29, ene.-feb. 2012. tab
Article in Spanish | LILACS | ID: lil-700975

ABSTRACT

Introducción. El término fimosis abarca distintas condiciones que van desde la presencia de un anillo fibroso hasta un prepucio asintomático pero no retráctil. Hasta hace algunos años, la circuncisión era la única opción disponible para el manejo de la fimosis. Sin embargo, diversos estudios y ensayos clínicos han evaluado el uso de esteroides tópicos para la liberación del prepucio fimótico. En el presente trabajo se evaluó el efecto del furoato de mometasona al 0.1% como tratamiento en la liberación de adherencias prepuciales y fimosis en niños mexicanos. Métodos. Se realizó un estudio retrospectivo y descriptivo en el que se incluyeron a 129 pacientes de 1 a 8 años de edad, a quienes se les aplicó furoato de mometasona al 0.1% en el prepucio y el glande una vez al día por 4 semanas y se les realizó una sinequiotomía al término del tratamiento. Resultados. Al realizar la sinequiotomía, se logró la retracción total del prepucio en 98% de los casos; de estos, 20% presentó recaída. En términos generales, la eficacia a largo plazo fue de 81% (IC 95% 73-89). Conclusiones. La aplicación tópica de furoato de mometasona al 0.1% fue eficaz para manejar la fimosis y liberar adherencias en el prepucio de niños mexicanos.


Background. In this study we evaluated the effect of mometasone furoate (0.1%) as a nonsurgical treatment of phimosis in Mexican children. Methods. We carried out a retrospective and descriptive study including 129 patients between 1 and 8 years old who were treated with the topical administration of 0.1% mometasone furoate on the prepuce and glans once daily for 4 weeks followed by sinechiotomy at the end of treatment. Results. After sinequiotomy, the foreskin was able to be fully retracted over the glans in 98% of the patients; however, in 20% of patients it returned to the original condition. Overall long-term efficacy was 81% (95% CI: 73-89). Conclusions. Topical administration of mometasone furoate (0.1%) was effective in the detachment of the foreskin of the prepuce from the glans, making it an effective, nonsurgical treatment for phimosis.

6.
Vaccine ; 28(46): 7414-9, 2010 Oct 28.
Article in English | MEDLINE | ID: mdl-20850536

ABSTRACT

Chagas disease is a major public health problem, with about 10 million infected people, and DNA vaccines are a promising alternative for the control of Trypanosoma cruzi, the causing agent of the disease. We tested here a new DNA vaccine encoding a combination of two leading parasite antigens, TSA-1 and Tc24, for the prevention and therapy of T. cruzi infection. Immunized Balb/c mice challenged by T. cruzi presented a significantly lower parasitemia and inflammatory cell density in the heart compared to control mice. Similarly, the therapeutic administration of the DNA vaccine was able to significantly reduce the parasitemia and inflammatory reaction in acutely infected Balb/c and C57BL/6 mice, and reduced cardiac tissue inflammation in chronically infected ICR mice. Therapeutic vaccination induced a marked increase in parasite-specific IFNγ producing CD4(+) and CD8(+) T cells in the spleen as well as an increase in CD4(+) and CD8(+) T cells in the infected cardiac tissue. In addition, some effect of the DNA vaccine could still be observed in CD4-knockout C57BL/6 mice, which presented a lower parasitemia and inflammatory cell density, but not in CD8-deficient mice, in which the vaccine had no effect. These results indicate that the activation of CD8(+) T cells plays a major role in the control of the infection by the therapeutic DNA vaccine, and to a somewhat lesser extent CD4(+) T cells. This observation opens interesting perspectives for the potentiation of this DNA vaccine candidate by including additional CD8(+) T cell antigens/epitopes in future vaccine formulations.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Chagas Disease/prevention & control , Protozoan Vaccines/immunology , Vaccines, DNA/immunology , Animals , Antigens, Protozoan/immunology , Chagas Disease/immunology , Heart/parasitology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Inbred ICR , Parasitemia/immunology , Parasitemia/prevention & control , Protozoan Vaccines/therapeutic use , Spleen/immunology , Spleen/parasitology , Trypanosoma cruzi/immunology , Vaccines, DNA/therapeutic use
7.
Toxicol Sci ; 100(2): 415-22, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17890764

ABSTRACT

Dermal exposure to military (JP-8) and/or commercial (Jet-A) jet fuel suppresses cell-mediated immune reactions. Immune regulatory cytokines and biological modifiers, including platelet activating factor (PAF), prostaglandin E(2), and interleukin-10, have been implicated in the pathway of events leading to immune suppression. It is estimated that approximately 260 different hydrocarbons are found in jet fuel, and the exact identity of the active immunotoxic agent(s) is unknown. The recent availability of synthetic jet fuel (S-8), which is refined from natural gas, and is devoid of aromatic hydrocarbons, made it feasible to design experiments to address this problem. Here we tested the hypothesis that the aromatic hydrocarbons present in jet fuel are responsible for immune suppression. We report that applying S-8 to the skin of mice does not upregulate the expression of epidermal cyclooxygenase-2 (COX-2) nor does it induce immune suppression. Adding back a cocktail of seven of the most prevalent aromatic hydrocarbons found in jet fuel (benzene, toluene, ethylbenzene, xylene, 1,2,4-trimethlybenzene, cyclohexylbenzene, and dimethylnaphthalene) to S-8 upregulated epidermal COX-2 expression and suppressed a delayed-type hypersensitivity (DTH) reaction. Injecting PAF receptor antagonists, or a selective cycloozygenase-2 inhibitor into mice treated with S-8 supplemented with the aromatic cocktail, blocked suppression of DTH, similar to data previously reported using JP-8. These findings identify the aromatic hydrocarbons found in jet fuel as the agents responsible for suppressing DTH, in part by the upregulation of COX-2, and the production of immune regulatory factors and cytokines.


Subject(s)
Cyclooxygenase 2/metabolism , Hydrocarbons/toxicity , Hypersensitivity, Delayed/drug therapy , Kerosene/toxicity , Skin/drug effects , Animals , Candida albicans/immunology , Cyclooxygenase Inhibitors/pharmacology , Dose-Response Relationship, Drug , Drug Combinations , Edema/chemically induced , Edema/drug therapy , Edema/immunology , Female , Foot , Hydrocarbons, Aromatic/toxicity , Hypersensitivity, Delayed/chemically induced , Hypersensitivity, Delayed/immunology , Immune Tolerance/drug effects , Immune Tolerance/immunology , Mice , Mice, Inbred C3H , Skin/metabolism , Skin Absorption/immunology , Specific Pathogen-Free Organisms , Up-Regulation
8.
Int J Exp Pathol ; 86(5): 323-34, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16191104

ABSTRACT

Although dengue virus (DV) enters through skin while mosquitoes feed, early contacts remain unexplored regarding the cutaneous viral fate and in situ immune responses. We addressed this by exposing healthy, non-cadaveric, freshly obtained human skin explants to a human DV2 isolate. We demonstrated negative-strand DV-RNA and non-structural protein-1, both suggestive of viral replication in skin. Although control, mock-infected and DV-infected explants showed less (MHC-CII(+)/CD1a(+)/Langerin+) Langerhans cells, deranged morphology and decreased frequency were more apparent in DV-infected explants. Whereas DV+ cells were infrequent in epidermis and completely absent in dermis, some areas of basal epidermis were clearly DV+, presumably keratinocytes, cells where TUNEL positivity revealed apoptosis. Unlike fresh, control and mock-infected skin, DV-infected explants expressed CD80 and CD83, indicative of dendritic cell (DC) activation and maturation, respectively. However, sequential sections indicated that these cells were not DV+, suggesting that activated/mature DCs capable of priming T cells, probably, were not infected. Alternatively, the occasionally infected epidermal DC might not have reached maturation. Interestingly, skin DV infection apparently uncouples the DC activation/maturation process from another crucial DC function, the subsequent migration into dermis. This was suggested, because upon cutaneous DV infection, the few emerging CD83+ (mature) DCs remained within the outer epidermis, while no dermal CD83+ DCs were observed. These paradoxical effects might represent unknown DV subversion strategies. This approach is relatively easy, quick (results in 48 h), economical for developing countries where dengue is re-emerging and advantageous to evaluate in situ viral biology, immunity and immunopathology and potential antiviral strategies.


Subject(s)
Dendritic Cells/immunology , Dengue Virus/pathogenicity , Dengue/immunology , Epidermis/immunology , Apoptosis , Dendritic Cells/virology , Epidermis/pathology , Epidermis/virology , Female , Humans , In Situ Hybridization , RNA, Viral/analysis , Reverse Transcriptase Polymerase Chain Reaction , Tissue Culture Techniques , Vaccination/methods , Viral Nonstructural Proteins/analysis , Virology/methods , Virus Replication
SELECTION OF CITATIONS
SEARCH DETAIL
...